Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Current Assets (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Current Assets for 7 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For Q3 2025, Current Assets rose 42.76% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, up 42.76%, while the annual FY2024 figure was $4.2 million, 47.35% down from the prior year.
  • Current Assets hit $5.1 million in Q3 2025 for Cyclerion Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $73.0 million in Q2 2021 and bottomed at $3.5 million in Q3 2024.
  • Average Current Assets over 5 years is $21.7 million, with a median of $8.3 million recorded in 2023.
  • Year-over-year, Current Assets plummeted 80.54% in 2023 and then surged 42.76% in 2025.
  • Cyclerion Therapeutics' Current Assets stood at $55.5 million in 2021, then tumbled by 73.28% to $14.8 million in 2022, then plummeted by 45.86% to $8.0 million in 2023, then crashed by 47.35% to $4.2 million in 2024, then rose by 19.88% to $5.1 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $5.1 million, $4.0 million, and $4.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.